Benefit
Battle Intensifies in the Obesity Drug Market as Novo Nordisk and Eli Lilly Vie for Dominance
obesity drugs; GLP-1; Wegovy; Zepbound; Novo Nordisk; Eli Lilly; market competition; direct-to-consumer; pharmacy benefit managers; compounders; clinical trials
Merck Terminates Midstage Asset from $1.9B Pandion Acquisition over Lack of Clinical Benefit
Merck; Pandion Therapeutics; asset termination; clinical trial; lack of benefit; biotech acquisition
AstraZeneca Highlights Survival Benefit for Tagrisso Combo Amid Competition in Lung Cancer
AstraZeneca; Tagrisso; lung cancer; Johnson & Johnson; EGFR-mutated NSCLC; overall survival; chemotherapy combination; FLAURA2 trial; life-extension benefit
J&J’s Stelara Revenue Plummets as Biosimilar Competition Intensifies in 2025
Stelara; Johnson & Johnson; ustekinumab; biosimilars; revenue decline; Q2 2025; pharmacy benefit managers; formulary exclusion; drug pricing; autoimmune disease
Corcept Highlights Survival Benefit Despite ALS Trial’s Missed Primary Endpoint
Corcept Therapeutics; dazucorilant; ALS; amyotrophic lateral sclerosis; DAZALS trial; survival benefit; phase 2 study; ALSFRS-R; ENCALS 2025
Johnson & Johnson Announces $55 Billion Investment in U.S. Manufacturing and Innovation
This major investment demonstrates J&J’s commitment to expanding its U.S. manufacturing and innovation capabilities, with potential benefits for job creation and the domestic pharmaceutical industry. The announcement aligns with broader trends of increased U.S. manufacturing investment by large corporations in recent years.
FTC Targets Pharmacy Benefit Managers Over Exorbitant Price Hikes on Specialty Generic Drugs
FTC, Pharmacy Benefit Managers, PBM, Specialty Generic Drugs, Price Hikes, Healthcare Costs
FTC Report Reveals Big 3 PBMs Made $7.3 Billion from Excessive Markups on Specialty Generic Drugs
FTC report, Big 3 PBMs, Specialty generic drugs, Price markups, Healthcare costs, Pharmacy benefit managers
Merck Enters Obesity Market with $2 Billion Deal for Chinese Oral GLP-1 Drug
Merck, Obesity, Oral GLP-1, Hansoh Pharma, HS-10535, Weight Loss, Cardiometabolic Benefits
Corcept’s ALS Drug Trial Misses Primary Endpoint, Yet Shows Promising Survival Benefit
Corcept Therapeutics, Dazucorilant, ALS (Amyotrophic Lateral Sclerosis), Phase 2 trial, Survival benefit, Fast Track Designation, Cortisol modulator